Stemline Therapeutics Inc (NASDAQ:STML) has been given an average recommendation of “Buy” by the eight ratings firms that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $33.75.
A number of analysts have weighed in on the company. Zacks Investment Research downgraded Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 9th. HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of Stemline Therapeutics in a research report on Friday, February 2nd. ValuEngine raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BidaskClub raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 26th.
In related news, COO Kenneth Hoberman sold 11,943 shares of the firm’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $14.18, for a total value of $169,351.74. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider David Gionco sold 4,250 shares of the firm’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $13.43, for a total transaction of $57,077.50. The disclosure for this sale can be found here. Insiders have sold a total of 42,216 shares of company stock worth $591,925 in the last three months. Insiders own 15.70% of the company’s stock.
Shares of Stemline Therapeutics (NASDAQ:STML) opened at $15.55 on Wednesday. Stemline Therapeutics has a 1-year low of $6.35 and a 1-year high of $17.40. The firm has a market capitalization of $450.51, a PE ratio of -6.05 and a beta of -0.02.
Stemline Therapeutics Company Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.